Virtual Library
Start Your Search
E. Eleptheriadou
Author of
-
+
P1.07 - Poster Session with Presenters Present (ID 459)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.07-034 - Somatostatin Receptors Expression in Small Cell Lung Cancer Patients (ID 5242)
14:30 - 14:30 | Author(s): E. Eleptheriadou
- Abstract
Background:
Somatostatin receptors have been described on the membrane of neoplastic cells and their expression has also been demonstrated on small cell lung cancer (SCLC). In this study we examined if the expression of somatostatin receptors at the time of disease progression correlated with survival and time to progression (TTP) of SCLC patients.
Methods:
10 patients with SCLC were studied using 111In-octreotide (111In-OCT) scintigraphy at diagnosis and disease progression. Scintigraphic examinations were performed following intravenous (i.v.) injection of 111 MBq 111In-OCT with whole-body scintigraphy and planar scintigraphy of the thorax as well as the SPECT technique .The scintigraphic results were expressed in comparison with soft tissue intake (normal prices <1.5).
Results:
111In-OCT was positive in all 10 SCLC patients at the time of diagnosis and progression of the disease. No statistical correlation was found between somatostatin receptors expression at the progression- mainly subtype 2( SSTR 2)- and survival (p=0.43), nor TTP(p=0.25) .Also the difference in somatostatin receptors expression during diagnosis and progression had no statistical correlation with survival and TTP.
Conclusion:
The clinical utility of receptor status characterization obtained with 111In-OCT scintigraphy is rather confined. Our study shows that 111In-OCT scintigraphy, although is a reliable, non-invasive technique to detect primary SLCL and its locoregional or distant metastases, cannot be used as a prognostic or predictive factor in SCLC patients.
-
+
P3.02c - Poster Session with Presenters Present (ID 472)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-101 - Immunotherapy with Nivolumab in NSCLC Patients: One Centre Preliminary Results (ID 5239)
14:30 - 14:30 | Author(s): E. Eleptheriadou
- Abstract
Background:
Nivolumab is an IgG4 monoclonal antagonist antibody to PD-1 that is approved for the treatment of patients with advanced squamous and non-squamous NSCLC with progression of disease on or after standard platinum-based chemotherapy, regardless of tumor PD-L1 protein expression. The aim of our study is to evaluate the efficacy and safety of nivolumab in this group of patients.
Methods:
We enrolled 23 patients with squamous and non-squamous NSCLC, stage IIIB-IV,19 males and 4 females, with median age 68 years who had failed two or more lines of systemic platinum based chemotherapy. All patients received at least 4 doses of nivolumab as monotherapy, at a dose of 3 mg/kg once every 2 weeks intravenously, until disease progression or unacceptable toxicity.
Results:
3 (13%) of 23 patients had an objective response as assessed by RECIST criteria and all of the responses were ongoing at the time of analysis. 19 (82.6%) of 23 patients had stable disease and one experienced progression of the disease. 2 (9%) of 23 patients reported treatment-related adverse events, including peripheral edema ,one (4%) with pleural effusion and one (4%) with pericardial effusion, which all were well tolerated and treated. No deaths were attributed to nivolumab.
Conclusion:
Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, resistant, squamous and non squamous non-small cell lung cancer.
